DE3577839D1 - Mit tritium markierte n-senfartige verbindungen und verfahren zu ihrer herstellung. - Google Patents

Mit tritium markierte n-senfartige verbindungen und verfahren zu ihrer herstellung.

Info

Publication number
DE3577839D1
DE3577839D1 DE8585301010T DE3577839T DE3577839D1 DE 3577839 D1 DE3577839 D1 DE 3577839D1 DE 8585301010 T DE8585301010 T DE 8585301010T DE 3577839 T DE3577839 T DE 3577839T DE 3577839 D1 DE3577839 D1 DE 3577839D1
Authority
DE
Germany
Prior art keywords
sened
tritium
signed
connections
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585301010T
Other languages
English (en)
Inventor
Abraham Fisher
Israel Hanin
Donald J Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Application granted granted Critical
Publication of DE3577839D1 publication Critical patent/DE3577839D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0442—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE8585301010T 1984-10-18 1985-02-15 Mit tritium markierte n-senfartige verbindungen und verfahren zu ihrer herstellung. Expired - Lifetime DE3577839D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/662,276 US4795627A (en) 1984-10-18 1984-10-18 Tritium labelled N-mustard type compounds and a process for their production

Publications (1)

Publication Number Publication Date
DE3577839D1 true DE3577839D1 (de) 1990-06-28

Family

ID=24657100

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585301010T Expired - Lifetime DE3577839D1 (de) 1984-10-18 1985-02-15 Mit tritium markierte n-senfartige verbindungen und verfahren zu ihrer herstellung.

Country Status (5)

Country Link
US (1) US4795627A (de)
EP (1) EP0178743B1 (de)
CA (1) CA1271755A (de)
DE (1) DE3577839D1 (de)
IL (1) IL74352A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671071B2 (en) * 1990-08-30 1996-08-15 State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University, Portland, Oregon, and The University of Oregon, Eugene, Oregon, Johnson Hall, Substituted amidines having high binding to the sigma receptor and the use thereof
US8039266B2 (en) * 2006-09-15 2011-10-18 Colorado School Of Mines Methods to radiolabel natural organic matter by reduction with hydrogen labeled reducing agents
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2571357B1 (de) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemische verbindungen, zusammensetzungen und verfahren zur kinasemodulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies

Also Published As

Publication number Publication date
EP0178743A3 (en) 1986-12-17
EP0178743A2 (de) 1986-04-23
US4795627A (en) 1989-01-03
CA1271755A (en) 1990-07-17
IL74352A (en) 1989-07-31
EP0178743B1 (de) 1990-05-23

Similar Documents

Publication Publication Date Title
DE3577839D1 (de) Mit tritium markierte n-senfartige verbindungen und verfahren zu ihrer herstellung.
DE3586597D1 (de) Polyetherverbindungen und verfahren zu ihrer herstellung.
DE3780263D1 (de) Imidazopyridinverbindungen und verfahren zu ihrer herstellung.
DE3689726D1 (de) Verschlussdichtung und verfahren zu ihrer herstellung.
DE3674022D1 (de) Teilweise methylierte cyclodextrinen und verfahren zu ihrer herstellung.
DE3583721D1 (de) Poroese folien und verfahren zu ihrer herstellung.
DE3682874D1 (de) Pyranoindolizinderivate und verfahren zu ihrer herstellung.
DE3482823D1 (de) Dihydropyridin-derivate und verfahren zu ihrer herstellung.
DE3874275D1 (de) Kollektoren und verfahren zu ihrer herstellung und ihrer verwendung.
DE3782994D1 (de) Erythromycin-a-derivate und verfahren zu ihrer herstellung.
DE3483957D1 (de) Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
DE3878510D1 (de) Fluessigkristalline verbindungen und verfahren zu ihrer herstellung.
DE3381627D1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
DE3878475D1 (de) Organopolysiloxanemulsion und verfahren zu ihrer herstellung.
DE3588039D1 (de) Azetidinonderivate und Verfahren zu ihrer Herstellung.
DE3878880D1 (de) Metall-keramik-verbindung und verfahren zu ihrer herstellung.
DE3482690D1 (de) Nukleare graphitkoerper und verfahren zu ihrer herstellung.
DE3879335D1 (de) Trifluorbenzolverbindungen und verfahren zu ihrer herstellung.
DE3776284D1 (de) Hydrolase und verfahren zu ihrer herstellung.
DE3587569D1 (de) Neue Amidoalkylmelamine und Aminoalkylmelamine und Verfahren zu ihrer Herstellung.
DE3765181D1 (de) Isocarbacycline und verfahren zu ihrer herstellung.
DE3673515D1 (de) Gonatrien-derivate und verfahren zu ihrer herstellung.
DE3584197D1 (de) Halbleitervorrichtung und verfahren zu ihrer herstellung.
DE3685013D1 (de) Amino-trifluormethylpyridinverbindung und verfahren zu ihrer herstellung.
DE3884551D1 (de) Radioaktive benzodiazepinderivate und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee